A meeting hosted by UK NEQAS ICC & ISH

at

The Tower Hotel Conference Centre
St Katharine's Way, London E1W 1LD

21st Century Slide Based Pathology & Molecular Diagnostics: From the Laboratory to the Patient

For Registration Details go to Meeting Voice:

http://www.meetingvoice.co.uk/Events.html

You will need to enter the access code: UKNEQAS
Lung Cancer: pathology, personalised therapy & related biomarkers

13.05 Companion Diagnostic Testing & Lung Cancer: The Birmingham Experience:  
**Dr Phillipe Taniere**, Consultant Pathologist, Queen Elizabeth Hospital, Birmingham

13.50 Personalized Medicine and Lung Cancer: **Dr Shobhit Baijal**, Consultant Medical Oncologist, Heartlands Hospital, Birmingham

14.30 EQA for ALK, PD-L1 & ROS-1 modules, an update: **Suzanne Parry**, UKNEQAS-ICC&ISH Scheme Manager

15.00 Coffee and Trade

Presentations by commercial companies

15.30 Evolution of PD-L1 scoring methods and cut-offs in the development program of pembrolizumab: **Nikos Lioutas** Biomarker and Diagnostics Director, Merck, Sharp & Dohme (MSD) UK

16.15 Progesterone Receptor: The neglected breast receptor! **Dr Ian Milton** Director, Histocyte Laboratories

17.30 Summary and discussion with all speakers

Meeting ends at 17.45

There will be a Buffet Dinner on Friday Evening From 19.30
Scientific Symposium Sponsored by Roche Diagnostics Ltd

PD-L1 Biomarkers in Bladder Cancer and Personalised Healthcare

15.20 Welcome & Introductions – Dr Tim Crossman, Roche Diagnostics

15.30 Low PDL-1 expression as a marker of resistance for immunotherapy in bladder cancer? 
Dr Mark Kockx, Consultant Pathologist, HistoGeneX Laboratories

16.00 PDL-1 Testing using the SP142 assay in Urothelial Carcinoma - The Birmingham experience: Dr Philippe Taniere, Consultant Pathologist – QE Birmingham

16.30 PDL-1 SP142 assay and Interpretation in mUC: Dr Corrado D’Arrigo, Consultant Pathologist, Poundbury Cancer institute

17.00 Changing landscape in the management of advanced bladder cancer: Professor Syed Hussain - Professor of Medical oncology at University of Sheffield, Department of Oncology and Metabolism

17.30 Summary and discussion with all speakers

Meeting ends at 17.45

Buffet Dinner Friday Evening From 19.30 pm
Tower Hotel Conference Room 1
Saturday 10th November 2018

Targos & Roche Joint Symposium: Predictive Cancer Pathology of Lung & Urothelial Cancer

9.00 Introduction by Dr Eslie Dennis, Vice President Medical Affairs, Ventana & Professor Bharat Jasani, Director of Pathology, Targos Molecular Pathology GmbH

9.05 Navigating the Complex Immuno-Oncology Landscape: Dr Eslie Dennis.

The Gerry Reynolds Lecture

9.50 PD-L1 Immune Checkpoint Analysis: Emerging Concepts: Professor Bharat Jasani

10.30 Coffee & Trade

11.00 PD-L1 Training Experience I: Microscopy vs Digitalized Images: Dr Gudrun Baenfer, Head of Advanced Training Unit, Targos Molecular Pathology GmbH

11.30 PD-L1 Training Experience II: Online Training: Dr Rolf Dietzko, Deputy Head of Advanced Training Unit, Targos Molecular Pathology GmbH

12.00 PD-L1 IHC - Tumour Cell (TC) interpretation and scoring: Dr Kathrina Alexander, Pathology Unit, Targos Molecular Pathology GmbH

12.45 Lunch & Trade

14.15: How to Validate Predictive Immunohistochemistry Testing in Pathology? / A Practical Approach Exploiting the Heterogeneity of Programmed Death Ligand-1 Present in Non–Small Cell Lung Cancer: Dr Erik Thunnissen, Consultant pathologist, VUMC, Amsterdam

14.45 Workshop 1b: PD-L1 IHC –Immune Cell (ICP) interpretation and scoring: Dr Bryce Porter, Consultant Pathologist, Ventana

15.30 Tea & Trade

16.00 Workshop 1c: PD-L1 IHC – Combined Positive Score (CPS) interpretation and scoring: Professor Bharat Jasani

16.45 Panel Discussion with speakers

17.45 Summing up and closing remarks by joint chairs

Meeting closes at 18.00.

Gala Dinner and Entertainment From 19.30 pm
Tower Hotel Conference Room 2
Saturday 10th November

Targos & UKNEQAS ICC & ISH Joint Symposium Predictive Cancer Pathology of Breast & GI Tract Cancer

8.30 Introduction by Professor Josef Reuschoff CMO, Targos Molecular Pathology GmbH & Dr Ian Frayling, Institute of Medical Genetics, University Hospital of Wales

8.35 Breast and Gastric cancer HER-2 updates: Professor Josef Reuschoff

9.20. Recent advances in understanding Lynch and Lynch-like syndromes: Dr Ian Frayling, Institute of Medical Genetics, University Hospital of Wales

10.00: GI Tract cancer, mismatch repair staining, problems and pitfalls: Professor Mark Arends, Head of Division of Pathology, University of Edinburgh

10.40 Coffee & Trade

11.10: Standardisation of Ki67 for breast cancer prognostication: Andrew Dodson, Deputy Scheme Director, Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital.

11.50 Her2 interpretation in breast and gastric cancer can sometimes be challenging: Dr Iris Nagelmeir, Targos Molecular Pathology GmbH

12.30 Lunch & Trade

14.00 Introduction by Dr Mark Kockx, CEO & Lead Pathologist, Histogenex

14.05: An overview of the MMR EQA Module - procedure and performance of participants: Jamie Hughes, Deputy Scheme Manager


15.15 Tea and Trade

Selected Topics

15.45: Modernising pre-analytical practices in line with the needs of companion diagnostics testing: Dr Mark Kockx

16.30 The challenges of implementing a PD-L1 proficiency testing program in Australia and RCPAQAP Update: Julia Pagliuso, Scheme Manager for Tissue Disciplines, RCPAQAP

17.15: The IQNPath Digital Portal: Dr Sarah Wedden, CADQAS, Poundbury Cancer Institute.

17.45 Summing up and closing remarks by chairman.

Meeting closes at 18.00

Gala Dinner and Entertainment From 19.30 pm
Digital Pathology

9.00 Introduction by Chairman: Suzanne Parry

9.05 Digital Pathology in the NHS – Future Proofing Diagnostic Services: Dr Bethany Williams, Leeds University Hospital

9.50 The possibilities offered by the use of artificial intelligence in slide-based pathology: Martin Kristensson, Visiopharm

10.30 Refreshments & Trade

Selected Topics

11.00 Keeping up with the clinical changes – Molecular Pathology EQA, Dr Jenni Fairly, Deputy Scheme Director, UKNEQAS-Molecular Genetics

11.40 How useful is Immunohistochemical detection of V600E BRAF mutation for malignant melanoma? Dr Guy Orchard, St John’s Dermatopathology, St Thomas’s Hospital

12.20 NTRK testing in solid tumours: Dr Patricia Carrigan, Head Oncology Regulatory Affairs Companion Diagnostics, Bayer Pharmaceuticals

12.55 Summing Up and closing remarks by Chairman
Workshops on 12th Floor of Tower Hotel
Saturday 10th November
Britannia Conference Room

Visiopharm Workshop
12.30 – 14.00
To include a presentation on Digital Image Analysis for Clinical and Quality Control Measurements: Andreas Schønau

Buffet Lunch provided

Workshops on 12th Floor of Tower Hotel
Sunday 11th November
Discovery Conference Room

Roche Digital Slide Viewing and Education (limited attendance to 20 individuals per topic)

From 10.00 - 13.00
Digital Classroom time examining IHC staining for the following antibodies and assays:

VENTANA MMR IHC Panel and BRAF V600E with Dr. Bryce Portier (35 min)
Experience staining of colorectal cancer (CRC) samples stained for MLH1, PMS2, MSH2, MSH6, and BRAF V600E for use in determination of the MMR status of a tumor, universal screening for potential Lynch syndrome, and stratification of sporadic tumors (BRAF V600E).

VENTANA DLL3 (SP347) Assay with Dr. Richard Huang (35 min)
Experience staining of resections, biopsies, and cytology samples (fine needle aspirations) of small cell lung cancer with DLL3 (SP347). Discuss data surrounding repeatability and precision of the DLL3 (SP347) assay.

VENTANA ALK (D5F3) CDx Assay with Dr. Bryce Portier (35 min)
Observe ALK staining on non-small cell lung cancer (NSCLC) samples with the D5F3 clone and discuss interpretation for aid in identifying patients eligible for treatment with crizotinib, ceritinib, or alectinib.

ROS1 (SP384) with Dr. Richard Huang (35 min)
Experience IHC staining of NSCLC resection samples with the ROS1(SP384) antibody clone. Discuss data surrounding IHC correlation with FISH status and reader precision study.

VENTANA pan-TRK (EPR17341) Assay with Dr. Bryce Portier (35 min)
Experience staining of pan-tumour samples with pan-TRK (EPR17341) in various tumour types. Discuss staining patterns in various tissues with wild-type pan-TRK and NTRK gene fusions, in relation to relevant adult and paediatric cancers

Coffee Provided
Workshops on 12th Floor of Tower Hotel
Sunday 11th November
Britannia Conference Room

From 10.00-13.00

**Non-gynae cytology workshop:**

**Limited attendance (maximum of 20-25)**

**The Quality of ICC on Cytology Samples - Is Brown/Red Good Enough?**

10.00 – 10.30: UK NEQAS Cytology Module – An Overview;  
**Neil Bilbe**, UK NEQAS ICC & ISH Support Scientist

11.00 – 13.00: An Interactive Session led by:  
**Dr Irena Srebotnik**, Institute of Pathology, Faculty of Medicine, University of Ljubljana, Slovenia

**Coffee Provided**

**13.00 Lunch Downstairs and Depart**